title: Donors With Hepatitis B Surface Antigen Positivity.
abstract: OBJECTIVE
  There is a still controversy among transplantation centers regarding acceptance of hepatitis B surface antigen (HBsAg)-positive donors for renal transplantation. However, some reports show that these donors can be used under a special protocol. In this study, we compared the clinical and biochemical parameters of patients who received kidneys from HBsAg-positive (group 1) versus other living-related kidney donors (group 2).
  
  
  METHODS
  We retrospectively analyzed the outcomes of 2168 living-related renal transplantations performed between December 2008 and April 2014 at Medical Park Hospital Transplantation Center, Antalya, Turkey. One hundred eleven donors were HbsAg-positive (group 1), and 2057 donors were HbsAg-negative (group 2). Group 1 kidney transplantations were undertaken only if the recipient displayed a hepatitis B antibody titer >10 mIU/mL and donor hepatitis B virus DNA was negative.
  
  
  RESULTS
  Demographic characteristics; 1-, 2- and 4-year serum creatinine levels; glomerular filtration rates; and liver function test results were similar between the two groups. There were no new hepatitis B virus infections throughout the study period. Acute rejection rates (26/111 in group 1 vs 375/2168 in group 2; P = .887), graft loss (4/111 in group 1 vs 123/2168 in group 2; P = .546), and patient loss (6/111 in group 1 vs 102/2168; P = .132) were similar between the two groups.
  
  
  CONCLUSIONS
  Our study showed that hepatitis B surface antigen positivity was not a contraindication to living-kidney donation.
authors.affiliation: Department of Nephrology and Renal Transplantation, Atakent Education and Research Hospital, Acıbadem University, İstanbul, Turkey. Electronic address: asuman.yavuz@gmail.com.
authors.forename: H
authors.initials: H
authors.lastname: Asuman Yavuz
authors.affiliation: Department of General Surgery and Transplantation Unit, Medical Park Hospital, Kemerburgaz University, Antalya, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Tekin
authors.affiliation: Department of General Surgery and Transplantation Unit, Medical Park Hospital, Antalya, Turkey.
authors.forename: Y
authors.initials: Y
authors.lastname: Yuksel
authors.affiliation: Department of Cardiology, Medline BSK Lara Hospital, Antalya, Turkey.
authors.forename: I
authors.initials: I
authors.lastname: Ateş
authors.affiliation: Organ Transplantation Coordination Unit Medical Park Hospital, Antalya, Turkey.
authors.forename: L
authors.initials: L
authors.lastname: Yucetin
authors.affiliation: Department of Biochemistry, Medical Park Hospital, Antalya, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Demir
authors.affiliation: Department of Clinical Microbiology and Infectious Disease, Medical Park Hospital, Antalya, Turkey.
authors.forename: B
authors.initials: B
authors.lastname: Uygun
authors.affiliation: Department of Nephrology, Medical Park Hospital, Kemerburgaz University, Antalya, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Tuncer
authors.affiliation: Department of General Surgery and Transplantation Unit, Medical Park Hospital, Antalya, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Demirbas
mesh_terms: D000328:Adult; D046148:Donor Selection / Q000706:statistics & numerical data*; D005260:Female; D005919:Glomerular Filtration Rate; D006085:Graft Survival; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014421:Turkey
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens